Kyo-Diagnostics K.K.

Company Name:Kyo-Diagnostics K.K.

Company Overview:
Kyo Diagnostics K.K. established in 2016 as a Kyoto University spin-off venture, aims to advance personalized cancer treatment. The company develops drug sensitivity testing using patient-derived cancer stem cell spheroids and next-generation diagnostic systems. Notably, it has achieved success in colorectal cancer treatment through its Patient-Derived Spheroid Xenograft (PDSX) model. Currently, the company is also working on drug sensitivity testing for multiple organs, contributing to the realization of highly accurate personalized therapies.

Purpose of the exhibition:

At this exhibition, our goal is to expand opportunities for collaboration with researchers and organizations that share our vision as partners in advancing medical innovation. By utilizing our platform, we aim not only to accelerate your research projects but also to support the development of contract research platforms. We are also actively working on establishing partnerships and collaborative frameworks across various countries, seeking opportunities for mutual growth and success. Through this event, we will showcase cutting-edge technologies and solutions in the field of personalized cancer treatment, particularly our innovative Patient-Derived Spheroid Xenograft (PDSX) model and advanced drug sensitivity testing methods. These technologies are designed to accelerate research and development, enabling the realization of more accurate and effective therapeutic strategies. Additionally, we are seeking partners interested in adopting our services, as well as collaborators for joint research and contract research projects. We look forward to the opportunity to collaborate with you.iagnostics.jp/

Company Website: https://kyo-diagnostics.jp